In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $10.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andres Y. Maldonado’s rating is based on Zentalis Pharmaceuticals’ strategic advancements and promising clinical developments. The company is focused on its Cyclin E1+ strategy, particularly with azenosertib, which is being tested in pivotal trials for platinum-resistant ovarian cancer, a condition with significant unmet medical needs. The potential for accelerated approval of azenosertib in this indication represents a near-term value driver for the company.
Moreover, Zentalis is expanding its research into other tumor types by exploring combinations of azenosertib with other therapies, such as T-DXd, in HER2-expressing tumors. This expansion into new solid tumor opportunities demonstrates Zentalis’ commitment to broadening the reach of its therapies. The company’s methodical approach and evidence-based platform reinforce the Buy rating, as these efforts are expected to enhance the therapeutic impact and commercial potential of their lead asset.